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Deregulation of Notch1 pathway 
and circulating endothelial 
progenitor cell (EPC) number in 
patients with bicuspid aortic valve 
with and without ascending aorta 
aneurysm
Carmela R. Balistreri  1, Floriana Crapanzano1, Leonardo Schirone  2, Alberto Allegra3, 
Calogera Pisano4, Giovanni Ruvolo4, Maurizio Forte5, Ernesto Greco6, Elena Cavarretta  2, 
Antonino G. M. Marullo2, Sebastiano Sciarretta2,5 & Giacomo Frati2,5
Bicuspid aortic valve (BAV) is frequently associated with the development of ascending aortic 
aneurysm, even if the underlying mechanisms remain to be clarified. Here, we investigated if a 
deregulation of Notch1 signaling pathway and endothelial progenitor cells (EPCs) number is associated 
with BAV disease and an early ascending aortic aneurysm (AAA) onset. For this purpose, 70 subjects 
with BAV (M/F 50/20; mean age: 58.8 ± 14.8 years) and 70 subjects with tricuspid aortic valve (TAV) 
(M/F 35/35; mean age: 69.1 ± 12.8 years) and AAA complicated or not, were included. Interestingly, 
patients with AAA showed a significant increase in circulating Notch1 levels and EPC number than 
subjects without AAA. However, circulating Notch1 levels and EPC number were significantly lower 
in BAV subjects than TAV patients either in the presence or absence of AAA. Finally, Notch pathway 
was activated to a greater extent in aortic aneurysmatic portions with respect to healthy aortic 
fragments in both BAV and TAV patients. However, the expression of genes encoding components 
and ligands of Notch pathway in aortic tissues was significantly lower in BAV than TAV subjects. Our 
study demonstrates that BAV subjects are characterized by a significant decrease in both tissue and 
circulating levels of Notch pathway, and in blood EPC number than TAV patients, either in presence or 
absence of AAA disease.
Bicuspid aortic valve (BAV) is the most common congenital cardiac malformation, affecting approximately 1.3% 
of the population worldwide1. It may evolve into a non-homogeneous leaflet calcification and serious compli-
cations, occurring in about 33% of patients1–3. Among the serious complications, ascending aortic aneurysm 
(AAA) and dissection are frequent1. Aortic aneurysm development and rupture associated with BAV are likely the 
results of anomalous regulatory pathways in endothelial cells and vascular smooth muscle cells within the aortic 
media. Unfortunately, these mechanisms remain to be fully clarified. The elucidation of this aspect appears to be 
particularly important, since it may help to find new therapeutic targets for the prevention of the development 
and progression of AAA.
Accumulating lines of evidence demonstrated that an impairment of Notch signaling pathway is involved in 
the development and progression of aortic aneurysm, showing a dual effect4–6. On the one hand, Notch1 appears 
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to be activated in aortic aneurysms and either genetic or pharmacological attenuation of this pathway delays 
aneurysm progression6–9. On the other hand, the effects of Notch1 activation appears to be cell-dependent, and 
it was previously shown that Notch pathway is critical for the maintenance of vascular integrity and promotion 
of vascular repair4–6,10–14. Accordingly, a deregulation of Notch signaling pathway may be involved in the devel-
opment of vascular complications associated with BAV, since previous works showed that a mutation of Notch1 
gene sequence is frequently associated in subjects with BAV15,16. However, a direct comparison of the level of 
systemic and vascular activation of Notch signaling pathway between patients with TAV and BAV has never been 
performed.
Notch signaling pathway plays critical functions in the regulation of new vessel formation, neo-angiogenesis and 
vascular repair during stress6,14–16. These vascular functions controlled by Notch signaling pathway may partially 
involve the regulation of endothelial progenitor cells (EPC). In fact, it was previously demonstrated that Notch sig-
naling pathway promotes EPC differentiation and mobilization17,18. Interestingly, a reduction of EPC number and 
function was previously found to be associated with the formation of cerebral and aortic aneurysm and inversely 
correlated with the size of aortic aneurysms19,20. These data suggest that an impairment of EPC system is associated 
with derangements in vascular homeostasis and finally with the formation of vascular structure abnormalities.
Thus, we hypothesized that a deregulation of Notch1 signaling pathway and EPC number is associated with 
the presence of BAV, thereby early contributing to the development of AAA. Accordingly, the aim of our study 
was to investigate the interplay of Notch signaling pathway activity with EPC number, in BAV and AAA patholo-
gies in a cohort of patients with BAV or TAV.
Results
BAV and TAV patient characteristics. BAV and TAV patient’s features are summarized in Table 1. No 
significant differences were observed regarding the size of aorta dilatation between BAV and TAV cases affected 
by AAA. However, many BAV cases were affected by AAA. Specifically, of 70 BAV cases, 51 subjects (73%; 45 
males and 6 females; mean age: 50.6 ± 16.6 years) also showed AAA with respect to only 25 TAV cases affected by 
AAA (36%; 19 males and 6 females; mean age: 70.2 ± 8.9 years) (p = 0.00001, by χ2 test, respectively). However, 
in both two groups of cases, the aneurysm had a location in the tubular ascending aorta portion. Among the 51 
BAV patients with AAA, 35 (69%; stenotic or incontinent) showed a fibrocalcific valve and 8 (16%) a prolapsed 
valve (Table 1). The remaining 19 BAV subjects (27%; 5 males and 14 females; mean age: 57.38 ± 15.3 years) were 
not affected by AAA, even if they presented aortic valve stenosis (73%) and/or a fibrocalcific aortic valve (22%). 
In addition, the 25 TAV cases with AAA had a moderate valve incontinence and stenosis. The remaining 45 TAV 
subjects (64%; 16 males and 29 females; mean age: 66.2 ± 13.3 years) without AAA showed valve stenosis only in 
7 subjects (15%; 4 males and 2 females; mean age: 69.5 ± 12.4 years).
Circulating number of the four EPC populations in BAV vs. TAV groups. We examined whether 
there were significant differences in the circulating levels of EPC cell populations between the BAV and 
TAV groups. Four different populations of EPCs were quantified: (1) CD45dimCD133+KDR+ cells; (2) 
Variables
BAV  
N = 70
TAV  
N = 70 P
Demographic characteristics Age, mean (SD) 58.8 (14.8) 69.1(12.8) <0.0001
Male sex, No. (%)* 50 (71) 35(50) 0.009
Female sex, No. (%) 20 (29) 35 (50) 0.009
Body mass index, mean (SD) 26 (4.8) 26.3 (3.2) N.S.
Size and location of AAA Subjects affected (%) 51 (73) 25(36) 0.00001
Size (mm), mean (SD) 53.3 (7.4) 50.3 (6.9) N.S.
Location, No:
Tubular ascending aorta 51 (100) 25 (100) N.S.
Comorbidity conditions, No (%) CVD Family History 8 (11) 5 (7.1) N.S.
Smoking 26 (37) 20 (28) N.S.
Hypertension 55 (78) 50 (719 N.S.
Dyslipidemia 9 (13) 5 (7.1) N.S.
Diabetes mellitus 3 (4.2) 1 (1.4) N.S.
Renal failure 0 (0) 1 (1.4) N.S.
Dissection 0 (0) 0 (0) N.S.
Aortic valve pathology, No (%):
Normal 0 (0) 38 (54) 0.0001
Prolapse 8 (11) 0(0) 0.003
Vascular calcium fibrosis 35 (50) 7 (10) 2.4e-7
Atherosclerosis coronary syndrome, No(%): 2 (3) 1 (0.8) N.S.
Table 1. Demographic and clinical characteristics, comorbodity conditions, complications of 70 BAV and 
70 TAV subjects. *Percentage values on total BAV and TAV subjects. P = TAV vs. BAV, by t Student test for 
quantitative variables, or χ2 test for qualitative variables.
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CD45dimCD34+KDR+cells; (3) CD45dimCD34+CD133+KDR+triple positive cells; and 4) the subpopulation of 
CD45dimCD34+KDR+CXCR4+ EPCs. These four subtypes represent EPCs with a different level of maturation 
(see Materials and Methods Section).
As shown in Fig. 1A–D, the circulating number of all four EPC cell populations showed similar differences in 
diverse patient’s groups. Patients with BAV without AAA displayed the lowest circulating number of four EPC 
populations, which was significantly lower than that observed in TAV without AAA. Interestingly, both TAV and 
BAV groups with AAA showed a significant elevation in the number of the four EPC populations (see Fig. 1A–D) 
with respect to TAV and BAV groups without AAA. However, among patients with AAA, the circulating number 
of EPCs in BAV subjects was still significantly lower than that observed in TAV subjects. Of note, the slope of 
increase of immature EPC (population 1 and 2) in patients with AAA with respect to those without AAA tended 
to be higher in patients with BAV than those with TAV. However, no changes were observed regarding popula-
tion 3 and an opposite trend was found with regard to population 4, which represented the most mature form 
of EPC. Overall, these results may suggest that formation of EPC is boosted in patients with BAV and AAA as a 
compensatory mechanism for the reduction of their circulating number and for the presence of AAA. However, 
the maturation process of these cells is impaired in these patients leading to a lower yield of mature EPC.
Systemic plasma levels of Notch1, SDF-1, and VEGF molecules. The low levels of the four circu-
lating EPC populations detected in BAV groups led us to investigate eventual dysfunctions in the molecules 
involved in EPC physiological function and maturation, such as Notch 1 pathway, SDF-1, and VEGF molecules. 
Consequently, we first assessed the systemic levels of these molecules (see Table 2). Regarding Notch 1 pathway, 
we evaluated the levels of the soluble form, deriving from an alternative way of activation of Notch 1 pathway, 
which occurs in both physiological and pathological conditions. This way is principally mediated by several fac-
tors, such as proteins secreted by endothelial and smooth muscle cells, and it determines the dissociation of Notch 
1 extracellular domain and receptor activation21–24. Thus, we assessed the circulating levels of Notch soluble form 
in both BAV and TAV cases. Surprisingly, the comparisons of the data obtained on systemic levels of Notch1 
highlighted that BAV cases without AAA show the lowest levels of Notch1 with respect to non-complicated 
TAV individuals (see Table 2), suggesting a deregulation of this pathway. In addition, among patients with AAA, 
individuals with BAV also had significantly reduced plasma levels of Notch1 when compared to TAV subjects 
(Table 2). Furthermore, comparisons of plasma levels of VEGF and SDF-1 in the groups enrolled, which are 
known to play an important role in angiogenesis by recruiting endothelial progenitor cells, were also assessed. 
We found that the levels of these molecules were lower in BAV without AAA patients than those detected in TAV 
without AAA subjects. However, no differences were observed between BAV and TAV groups affected by AAA 
(see Table 2). Thus, we excluded that the reduction of EPC levels in BAV groups with AAA was secondary to a 
deregulation of VEGF and SDF-1 circulating levels.
Figure 1. Circulating levels of the four EPC populations detected in peripheral blood from the study 
population. (A–D) Circulating number of different EPC subpopulations was measured in different patient 
groups. Immunophenotype of the four EPC populations is displayed in the Figure. Of note, population 1 was 
CD34-negative, whereas population 2 was CD133-negative.
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Correlations between the four EPC cell populations and systemic factors. The data obtained on 
systemic molecules led us to determine which circulating factor was the strongest predictor for EPC number in our 
population. Consequently, we determined the potential correlations between the four EPC populations and Notch 
1, SDF-1, and VEGF molecules. Interestingly, we detected that the reduction of all the four EPC cell populations 
observed in BAV cases positively correlated only with the Notch 1 soluble molecule (r = 0.131, p = 0.01; r = 0.229, 
p = 0.02; r = 0.267, p = 0.001, r = 0.345, p = 0.0001, respectively; by non-parametrical Spearman correlation test; 
data not shown). This data was additionally confirmed by a generalized linear model with Poisson distribution 
and logarithm link. It showed that Notch1 was the only factor to be significantly associated with the three most 
relevant and functional EPC subpopulations, and particularly with the CD45dimCD34+KDR+CXCR4+EPC 
population (the most differentiated EPC population) (p < 2e-16; see Fig. 2A). In addition, by simply comparing the 
values of different circulating factors with the number of CD45dimCD34+KDR+CXCR4+EPC cells on the same 
graph, differences in Notch1 levels and EPC number among different groups showed the same trend (see Table 3).
Gene expression levels of Notch signaling components in aortic tissues from BAV and TAV 
patients and their tissue protein levels. To validate the significant reduction of levels of Notch1 in 
plasma samples of BAV cases, we also checked Notch signaling pathway in aortic tissues from patients with BAV 
and TAV affected by AAA undergoing surgery. We indeed evaluated the gene expression levels of all Notch recep-
tors (1–4), Notch ligands and Notch downstream targets (such as the Hairy and enhancer of split gene family 
(Hes), the Hes related gene family (Hey) and the Notch-regulated ankyrin repeat protein (NRARP)) in portions 
Systemic molecules examined
BAV without TAA  
N = 19
BAV with TAA  
N = 51 P
Notch-1 (pg/ml) 0.05 ± 3 11.3 ± 6 <0.0001
SDF-1 (pg/ml) 1256.2 ± 8 1998.2 ± 15 <0.0001
VEGF (pg/ml) 293 ± 13 408 ± 16 <0.0001
Systemic molecules examined TAV without TAA  N = 45
TAV with TAA  
N = 25 P
Notch-1 (pg/ml) 6.9 ± 3 21.6 ± 8 <0.0001
SDF-1 (pg/ml) 1658.8 ± 11 1995 ± 1 <0.001
VEGF (pg/ml) 389 ± 7 405 ± 2 <0.001
Systemic molecules examined BAV without TAA  N = 19
TAV without TAA  
N = 45 P
Notch-1 (pg/ml) 0.05 ± 3 6.9 ± 3 <0.0001
SDF-1 (pg/ml) 1256.2 ± 8 1658.8 ± 11 <0.001
VEGF (pg/ml) 293 ± 13 389 ± 7 <0.001
Systemic molecules examined BAV with TAA  N = 51
TAV with TAA  
N = 25 P
Notch-1 (pg/ml) 11.3 ± 6 21.6 ± 8 <0.0001
SDF-1 (pg/ml) 1998.2 ± 15 1995 ± 1 0.08
VEGF (pg/ml) 408 ± 16 405 ± 2 0.19
Table 2. Systemic plasma levels of Notch1, SDF-1, and VEGF. Vascular endothelial growth factor (VEGF), Stromal 
cell-derived factor- (SDF)-1. *By unpaired t-test with Welch correction.
Figure 2. Linear relationship between Notch-1 and CD45dimCD34+KDR+CXCR4+EPCs. Generalized linear 
model with Poisson distribution and logarithm link correlating circulating Notch1 soluble levels with EPC 
subpopulation. Statistical significance tested among all groups (P < 2E-16).
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of normal aorta and portions of aortic aneurysm harvested from patients underwent elective surgical repair. As 
shown in Fig. 3, all genes belonging to Notch signaling showed the same expression pattern. Notch signaling was 
activated in aneurysmatic portions with respect to aortic healthy tracts in both BAV and TAV patients. However, 
Notch expression levels were significantly lower in both aneurysms and normal aortic parts from subjects with 
BAV with respect to patients with TAV, confirming the previously described results obtained with circulating 
levels of soluble Notch1.
Discussion
Over the last couple of years, it has become increasingly evident that the Notch signaling pathway plays a pivotal 
role in the development and homeostasis of the cardiovascular system. The Notch signaling pathway is critical 
for cell fate determination during embryonic development, including many aspects of vascular development. An 
emerging paradigm suggests that the Notch gene regulatory network is often involved in vascular remodeling and 
repair in the context of several vascular diseases following injury.
Our study demonstrates that Notch signaling is activated in patients affected by AAA, both in the peripheral 
blood as well as in specimens of aneurysmatic tissues. These results were paralleled by an increase in the number 
of circulating EPCs in these subjects. Interestingly, Notch signaling activity and EPC number were significantly 
reduced in patients affected by BAV either in the presence or in the absence of AAA. Overall, these data suggest 
that a deregulation of Notch1 and EPC may be implicated in the development of BAV and the associated vascular 
complications.
Previous study demonstrated that derangements of Notch signaling are involved in the development of 
aortic aneurysms7–9. Notch signaling consists of four receptors (Notch1–4), with either overlapping or distinct 
functions, which bind to specific ligands (Jagged1/2; Delta-like1/3/4)4–6. Notch receptors and ligands are highly 
expressed in the vasculature, showing some differences in their expression pattern among different vascular 
cells and playing both physiological and pathological functions4–6. Notch signaling regulates vasculogenesis and 
endothelial mesenchymal transition during development4–6,11,12. Notch signaling was also shown to preserve vas-
cular integrity and to promote the formation of new vessels and vascular repair in response to stress10–14. Previous 
studies also demonstrated that Notch signaling components and precisely the extracellular domain can be found 
in circulating soluble forms eliciting receptor activation in a ligand-independent manner21–24.
Our study significantly extends this previous evidence by demonstrating that the entire Notch signaling path-
way is activated in thoracic aortic aneurysms with respect to normal aortic tissues. However, the aortic gene 
expression of all Notch receptors and ligands was found to be reduced in patients affected by BAV. BAV patients 
Amounts of circulating angiogenetic factors, 
Notch1 and the triple positive EPC cells
BAV without TAA 
N = 19
BAV with TAA 
N = 51
TAV without TAA 
N = 45
TAV with TAA 
N = 25
CD45dimCD34 + KDR + CXCR4 + EPCs 3.6 ± 1.2 25 ± 2.5 9 ± 3.4 81 ± 6.4
Notch-1 (pg/ml) 0.05 ± 3 11.3 ± 6 6.9 ± 3 21.6 ± 8
SDF-1 (pg/ml) 1256.2 ± 8 1998.2 ± 15 1658.8 ± 11 1995 ± 1
VEGF (pg/ml) 293 ± 13 408 ± 16 389 ± 7 405 ± 2
Table 3. Simple comparison of amounts of circulating angiogenetic factors, Notch1, and the triple positive EPC cells.
Figure 3. Expression levels of Notch signaling in aortic aneurysms. Significant differences were observed 
among the groups with the lowest levels detected in BAV groups than TAV cases and controls (see details in 
Result section). The statistical significance was tested as it follows: aneurysmatic aortic tissue from patients with 
BAV and AAA vs. aneurysmatic aortic tissue from patients with TAV and AAA (*P < 0.001); non-aneurysmatic 
aortic tissue from patients with TAV and AAA vs. aneurysmatic aortic tissue from patients with TAV and 
AAA(ϑP < 0.05); non-aneurysmatic aortic tissue from patients with TAV and AAA vs. aneurysmatic aortic 
tissue from patients with TAV and AAA (ψP < 0.001); non-aneurysmatic aortic tissue from patients with BAV 
and AAA vs. aneurysmatic aortic tissue from patients with BAV and AAA (§P < 0.001); non-aneurysmatic 
aortic tissue from patients with BAV and AAA vs. non-aneurysmatic aortic tissue from patients with TAV and 
AAA (πP < 0.001).
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with and without AAA also displayed a reduction in circulating levels of soluble Notch1 with respect to patients 
with TAV. Circulating Notch1 levels were also significantly lower in patients with BAV without AAA. These data 
are in agreement with previous study demonstrating that BAV condition is associated with genetic defects of 
Notch115,16 and may suggest that an impairment of the entire Notch signaling may contribute to the develop-
ment of aortic complications in patients affected by BAV. Certainly, future mechanistic studies are mandatory 
to corroborate this hypothesis. Of note, since Notch1 signaling deeply relies on the tissue microenvironment, 
future studies are necessary to evaluate whether these mechanisms may be involved in the inhibition of Notch1 
signaling in patients with BAV. It is possible that several mechanisms and interplays related to extracellular matrix 
and connective tissue remodeling in patients with BAV may contribute to the observed derangements. Genetic 
mechanisms may also be involved in the impairment of Notch1 signaling in patients with BAV. In fact, previous 
work showed that a mutation of Notch1 gene sequence is frequently associated in subjects with BAV15,16.
We also found that the reduction of circulating levels of soluble Notch1 in subjects affected by BAV are directly 
correlated with the reduction of circulating EPC number observed in these subjects. This result is in line with pre-
vious studies demonstrating that activation of Notch signaling pathway contributes to EPC mobilization and dif-
ferentiation during stress15,17. EPCs play a critical role in vascular repair processes during stress25–27. Accordingly, 
previous study demonstrated that an impairment of EPCs is associated with the development of cerebral and 
aortic aneurysms19,20. Indeed, it was demonstrated that the number of circulating EPCs in subjects with aortic 
aneurysm is inversely correlated with the severity of the disease19. This evidence may support the hypothesis that 
a deregulation of the Notch/EPC axis may represent a potential mechanism through which BAV condition is 
associated with an increased susceptibility to develop pathological aortic diseases. Future experimental studies 
are warranted to investigate the mechanisms underlying the impairment of Notch signaling and EPC in subjects 
with BAV.
Strengths and limitations. The strengths of the present study include the homogenous study population 
and the very comprehensive data regarding the population enrolled. Moreover, the data of this study are the 
result of a relatively small sample, since we focused our study on BAV, a disease with a very low prevalence. 
Nevertheless, our data are relevant, even if they need additional validation and confirmation. However, our study 
has limitations that should be acknowledged. The main limitation of the study relies on the fact that it was asso-
ciative, and we could not appropriately study the cause-effect relationship between Notch signaling, EPC, aortic 
aneurysm and BAV. Another limitation could be represented by the fact that age was lower in subjects with BAV 
thereby hypothetically interfering with the results. In fact, this depends on the early onset of complications in 
BAV cases than TAV cases. BAV should be considered a heterogeneous and multifaceted disease, with a great 
clinical impact, being associated with the onset of a large range of serious diseases, such as AAA and aortic dis-
section. Furthermore, we could not corroborate gene expression analyses in aortic specimens by checking also 
protein expression of different genes. Consequently, further and larger investigations are certainly needed. For 
example, genomic, transcriptomic and epigenetic investigations may eventually lead to a better understanding of 
the molecular and cellular mechanisms associated with AAA in BAV patients28.
Conclusions
In conclusion, our study demonstrates that subjects with BAV have a significant reduction of Notch signaling and 
EPC number with respect to patients with TAV, irrespective to the presence of AAA, suggesting a deregulation 
in Notch signaling and EPC in subjects with BAV (a suggested model is reported in Fig. 4A,B, defined as “model 
from funny to Eureka”). Furthermore, the results of this study confirm the data previously obtained in our recent 
investigations29–31, which suggest the presence of unique molecular and cellular mechanisms in AAA develop-
ment in BAV vs. TAV patients. Further and larger studies are certainly necessary to validate these findings and 
our suppositions. The reproducibility of our results from a very large sample size, enriched by clinical data, might 
provide the possibility of identifying potential molecular and genetic biomarkers useful to detect BAV subjects at 
high AAA risk, to monitor and treat them differently from those with TAV21,30–32. Thus, confirmation and valida-
tion of these emergent data could allow us to suggest specific clinical recommendations on the correct timing as 
well as the most appropriate surgical approach to use in the case of BAV patients with AAA and a normal aortic 
root in order to prevent or attenuate multiple possible complications, such as rupture or cerebral and periph-
eral adverse events. On the other hand, clarifying the issue concerning the surgical procedure with or without 
composite aortic root replacement represents the major aims of recent studies, since no clear and comprehen-
sive guidelines do currently exist. Furthermore, as mentioned above, this approach could allow us to identify a 
multi-biomarker profile to facilitate the management and outcome of this complex syndrome.
Material and Methods
Study population. Our study included a population of 70 BAV subjects (50 males and 20 females; mean age: 
58.8 ± 14.8 years) and 70 TAV subjects (35 males and 35 females; mean age: 69.1 ± 12.8 years) with or without 
AAA, as shown in Table 1. Patients of each group (precisely BAV with or without AAA, TAV with or without 
AAA) were recruited from January 2015 to December 2016. The cases were randomly selected from patients 
referring to the Units of Cardiac Surgery (Department of Surgery and Oncology, University of Palermo) and 
Cardiology, for surgery replacement or routine care screening. Appropriate exclusion criteria were also used 
during the BAV/TAV enrollment, for the following diseases: (a) cardiovascular diseases were excluded according 
to history and by detecting apposite laboratory and imaging biomarkers as indicated by the latest ESC or ASC 
guidelines; (b) connective tissue disorders were excluded by assessing markers of inflammation immunological 
(i.e. autoantibodies) and imaging biomarkers; (c) inflammatory diseases (from infections to hematological, gas-
trointestinal, urogenital, pulmonary, neurological, endocrinal inflammatory disorders, and neoplasies included) 
by detecting apposite laboratory parameters (including complete blood cell count, erythrocyte sedimentation 
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rate, glucose, urea nitrogen, creatinine, electrolytes, C reactive protein, liver function tests, iron, and proteins) 
and imaging biomarkers. In addition, all the enrolled cases belonged to the same ethnic group, since their parents 
and grandparents were born in Western Sicily. Thus, a very homogenous population was studied. Furthermore, 
elective or acute surgical treatment (using wheat operation, Bentall-De Bono and Tirone David surgical tech-
niques, whenever possible) and complementary tubular-ascending aorta resection were performed in the BAV 
and TAV patients with AAA after evaluation of aortic transverse diameter sizes by Computed Tomography 
scanning according to recent guidelines, as reported in our review31,33. Accordingly, an experienced physician 
evaluated aortic transverse diameter sizes by echocardiography (Philips Ie. 33) before either elective or urgent 
surgery. The dimension of the aortic annulus, sinuses of Valsalva, proximal ascending aorta (above 2.5 cm of the 
sino-tubular junction) and aortic arch were assessed pre-operatively by trans-thoracic echocardiography as well 
as in the operating theatre by trans-oesophageal-echocardiography before the institution of the cardiopulmonary 
bypass. These measures, together with demographic and clinical data (including co-morbidities) were obtained 
from patients’ medical records and are presented in Table 1. In all BAV and TAV cases, hypertension was treated 
by beta-blockers.
Ethical Study Approval. Our study was performed in accordance with ethical standards of the Helsinki 
Declaration of the World Medical Association and Italian legislation, and it received approval from Regional 
Ethics Board in Palermo (No. APUNIP0094517) and all participants gave their informed consent. Data were 
encrypted to ensure patient s’ privacy. All clinical measurements were performed in blind.
Flow cytometry quantification of the four EPC populations number. For the identifica-
tion and quantification of EPCs, we used a slightly modified version of a protocol proposed for the first time 
in 2010 by Schmidt-Lucke and co-workers34 and based on the International Society for Hematotherapy 
and Graft Engineering (ISHAGE) sequential gating strategy35 (see details in Supplementary Material). 
Briefly, 1 ml of blood was collected from a forearm vein into EDTA-coated tubes, transported in ice to 
the laboratory and processed within 1 to 2 hours after the collection. First of all, 150 μl of whole blood were 
incubated with the following combination of anti-human monoclonal antibodies: 10 μl of anti-CD133 conju-
gated with allo-phycocyanin (APC) (Milteny Biotec), 5 μl of anti-CD45 conjugated with APC-H7 (Becton 
Dickinson), 10 μl of anti-KDR (also known as type 2 vascular endothelial-growth factor receptor-VEGF-R2) 
conjugated with phycoerythrin (PE) (Sigma), 10 μl of anti-CD34 conjugated with fluorescein isothiocy-
anate (FITC) (Becton Dickinson) and 10 μl of anti-CD184 (also known as C-X-C chemokine receptor 
type 4 (CXCR4)) conjugated with PE-Cyanine 5 (PE-Cy5) (BD-Pharmingen) for 30 min at 4 °C, protected 
from light. Red blood cell lysis was performed using a 1:10 (v/v) water dilution of FACS Lysing Solution 
Figure 4. (A,B) Our model on the pathophysiological mechanisms underlying the development of BAV and its 
vascular complications, the model from funny to Eureka. In (A) we suggest that BAV is the result of alterations in 
Notch pathway, which determine a deregulation in both number and function of EPC cells, and consequently in 
the cardiovascular repair system. In (B) we evidence that all these alterations early induce vascular dysfunction 
and remodelling and consequently onset of AAA.
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(BD-Biosciences) and washed with phosphate-buffered-saline (PBS) before flow-cytometry acquisition. 
Data acquisition was performed with a BD-Bioscience FACSCanto II, a high-performance flow cytom-
eter, which can accurately analyse up to eight different fluorescent markers from many events. 
We used the flow cytometry software Infinicyt 1.5 (Cytognos) for the analysis. According to the Schmidt-Lucke’s 
and co-workers protocol, human circulating EPCs are identified by a minimal antigenic profile that includes at 
least one marker of stemness/immaturity (CD34 and/or CD133) and at least one marker of endothelial com-
mitment (KDR) (see details in Supplementary Material). CD45 staining was also performed to identify and 
consequently exclude leucocytes (see details in Supplementary Material). In fact, as previously summarized25,26, 
among these only CD45dim cells are considered circulating EPCs. In addition, we analysed CXCR4 (CD184), 
receptor of Stromal cell-derived factor 1 (SDF1), a cell surface antigen expressed on EPCs that plays a key role 
in their trans-endothelial migration and homing to sites of vascular injury. However, since isotype controls are 
known to mask rare cell populations, none were used in this analysis, and baseline fluorescence was determined 
using unstained cells. Moreover, EPCs are extremely rare events in peripheral blood, and thus require additional 
strategies to increase the sensitivity of the method and the accuracy of our work. These included: the automatic 
compensation to minimize fluorescence spillover, the exclusion of dead cells and the use of specific high-quality 
mononuclear antibodies25–27. The total number of acquired events was increased to a minimum of 1 million 
per sample, which is several folds larger than the number of events required for most other applications of flow 
cytometry. Thus, the results of counts from flow cytometry were expressed as the number of cells per 106, while 
standard deviations (SD) were reported beside the mean of each group. Circulating EPCs counts, performed in 
triplicate, were tested by a non-parametrical Spearman test, showing a strong statistical correlation (r = 0.83, 
P < 0.0001). These technological approaches were used for all the enrolled groups. In conclusion, we quantified 
four different populations of EPCs, similarly to Schmidt-Lucke and co-workers: (1) CD45dimCD133+KDR+cells; 
(2) CD45dimCD34+KDR+cells; (3) CD45dimCD34+CD133+KDR+triple positive cells; and (4) the subpopulation 
of CD45dimCD34+KDR+CXCR4+ EPCs.
Quantifications of systemic levels of Notch-1, VEGF, SDF-1 (CXCL12). Venous blood samples were 
collected from all enrolled subjects in a fasting state (more than 8 h without food administration). In BAV and 
TAV cases, blood samples were collected within the first 3 h of their admission. Plasma samples were obtained 
immediately after collection spinning whole blood (3500 rpm at 4 °C for 10 minutes) and then stored at −80 °C for 
further analysis. Plasma levels of VEGF and SDF-1 were measured by ELISA and commercial kits (R&D Systems, 
Minneapolis, MN, USA), according to the manufacturer’s instructions. Notch-1 systemic levels were also detected 
using an ELISA test (Cusabio, Baltimore, MD, USA). Precisely, we detected the soluble form of Notch-1 pathway, 
which represents the Notch Extracellular Domain (see Results and Discussion sections for its detailed description). 
Detection limits were 9 pg/ml, 3.9 pg/ml and 0.01 pg/ml for VEGF, SDF-1 and Notch-1 respectively. All assays 
were run in duplicate.
Transcription analyses by using Real-time PCR (qRT-PCR). Full aortic segments with resected nor-
mal as well as aneurysmatic aortic wall from tubular-ascending aorta were collected from patients with AAA. 
Specimens were fixed in 10% neutral buffered formalin and then processed for routine paraffin embedding. Total 
RNA was extracted by using the QiagenRNeasy FFPE kit, treated with DNase I enzyme (Promega) for 1 h at 37 °C 
and then cleaned by column purification (Qiagen). Total RNA concentration and quality were determined with 
a spectrophotometer. Then cDNA was prepared using 1–2 µg of RNA (Ready-To-Go, T-Primed First-Strand Kit, 
Amersham Bioscience). The synthesised cDNA was stored at −20 °C RT-PCR analysis. Quantitative polymerase 
chain reaction (qPCR) was subsequently performed using the SYBR Green (SIGMA) in a Light-Cycler (Roche). 
Cyclophilin and Rn18S transcripts were used as internal controls36. Primer sequences are illustrated in Table S1 
Supplementary Materials. The results were analysed using the 2−ΔΔCt (Livak) relative expression method.
Statistical analysis. Statistical analyses were performed using SPSS software version 20. Significant dif-
ferences among qualitative variables were calculated by using χ2 test. Continuous variables (including number 
of cells, levels of systemic blood molecules, and gene expression levels) were expressed as mean ± SD (Standard 
deviation). Distribution normality was assessed by Kolmogorov–Smirnov test. Unpaired t-test (Welch corrected) 
was utilised to analyse the data between two groups whereas one-way ANOVA or Kruskal-Wallis test followed 
by Bonferroni correction was applied to compare more than two groups. To identify possible correlations, a 
non-parametrical Spearman correlation test was also used. To determine the possible influence of Notch-1 on the 
EPC populations, we used a generalized linear model with Poisson distribution and logarithm link. Differences 
were considered significant when a p value < 0.05 was obtained by comparison between the different groups.
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